Clinical trials: Psilocybin, completed
Major Depressive Disorder, Depression
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
PROTOCOL SYNOPSIS Title The effect of psilocybin on Major depressive disorder (MDD) symptom severity and synaptic density - a single dose randomized, double blind, placebo-controlled phase 2b positron emission tomography study…
- Trial name
- PSIPET (NCT04630964)
- Testing
- Psilocybin, Niacin
- Where
- Sweden
- Volunteers
- 35 people
- Sponsor
- Section for Affective Disorders; Northern Stockholm Psychiatry
Obsessive-compulsive Disorder (OCD)
Psilocybin for Treatment of Obsessive Compulsive Disorder
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it…
- Trial name
- PSILOCD (NCT03300947)
- Testing
- Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Depression, Burnout, Professional
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
This project is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline…
- Trial name
- PAPR (NCT05557643)
- Testing
- Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Utah
Amnestic Mild Cognitive Impairment
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants…
- Trial name
- NCT06041152
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Psilocybin-assisted CBT for Depression
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2)…
- Trial name
- NCT05227612
- Testing
- Psilocybin, Cognitive behavioral therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Los Angeles
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Healthy
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02243813
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alcohol Dependence
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide…
- Trial name
- NCT01534494
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Healthy
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects
4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic…
- Trial name
- 2C-B (NCT05523401)
- Testing
- 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg)
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Cocaine-Related Disorders
Psilocybin-facilitated Treatment for Cocaine Use
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use.
- Trial name
- NCT02037126
- Testing
- Psilocybin, Diphenhydramine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Treatment Resistant Depression
Psilocybin for Treatment-Resistant Depression
The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression.
- Trial name
- NCT05029466
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Brain and Cognition Discovery Foundation
Obsessive-Compulsive Disorder
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PAP-OCD (NCT06299319)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre for Addiction and Mental Health
Alcohol Dependence
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence.
- Trial name
- NCT02061293
- Testing
- Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is…
- Trial name
- NCT06643637
- Testing
- Psilocybin
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Psychedelic Experiences, Amnesia
Pilot RECAP Study in Healthy Volunteers
The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin.
- Trial name
- RECAP (NCT04842045)
- Testing
- Psilocybin and Midazolam
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy Volunteer
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple…
- Trial name
- NCT07050368
- Testing
- Psilocybin
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MycoMedica Life Sciences PBC
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Healthy
Psilocybin and Spiritual Practice
This study will investigate the effects of psilocybin dose and the frequency and intensity of support activities for spiritual practice (e.g., meditation) on a battery of attitudinal and behavioral outcome measures in 75 healthy…
- Trial name
- NCT00802282
- Testing
- psilocybin, Intensity of support for spiritual practice, Number of sessions
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University